In a retrospective multicenter cohort study of 446 COVID-19 patients, early administration of inhaled IFNα2b produced more favorable clinical responses compared with lopinavir/ritonavir treatment alone and was associated with reduced in-hospital mortality (Wang et al., 2020). Here, IFNA2 is linked to COVID-19.